Literature DB >> 15003898

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Tiziano Barbui1, Giovanni Barosi, Alberto Grossi, Luigi Gugliotta, Lucio N Liberato, Monia Marchetti, Maria Gabriella Mazzucconi, Francesco Rodeghiero, Sante Tura.   

Abstract

BACKGROUND AND OBJECTIVES: The Italian Society of Hematology (SIE) and the two affiliated Societies (SIES and GITMO) commissioned a project to develop guidelines for the therapy of essential thrombocythemia (ET) using evidence-based knowledge and consensus formation techniques. DESIGN AND METHODS: Key questions on the optimal management of ET patients were formulated by an Advisory Council (AC) and approved by an Expert Panel (EP) composed of 7 senior hematologists. The AC systematically reviewed the published literature from 1980 to August 2002, and articles were graded according to their internal validity and quality. Using the Delphi technique, the EP was asked to answer the key questions according to the available evidence. From September 2002 to March 2003, four Consensus Conferences were held in accordance with the Nominal Group Technique with the goal of solving residual disagreement on recommendations.
RESULTS: The EP provided recommendations on when to start platelet-lowering therapy, the most appropriate platelet-lowering agent, the use of anti-platelet therapy, and the management of women in childbearing age and of pregnant women. INTERPRETATION AND
CONCLUSIONS: By using evidence and consensus, recommendations for the treatment of key problems in ET have been issued. Statements are graded according to the strength of the supporting evidence and uncertainty is explicitly declared.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003898

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  36 in total

Review 1.  Do we know more about essential thrombocythemia because of JAK2V617F?

Authors:  Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 2.  Special issues in myeloproliferative neoplasms.

Authors:  Tiziano Barbui; Guido Finazzi
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

Review 3.  Anagrelide: a review of its use in the management of essential thrombocythaemia.

Authors:  Antona J Wagstaff; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

5.  Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

Authors:  Tiziano Barbui; Alessandra Carobbio; Alessandro Rambaldi; Guido Finazzi
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

6.  Platelet count in essential thrombocythemia: the more the better?

Authors:  Ayalew Tefferi
Journal:  Blood       Date:  2008-10-15       Impact factor: 22.113

7.  Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

Authors:  Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro M Vannucchi; Federica Delaini; Vittoria Guerini; Marco Ruggeri; Francesco Rodeghiero; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2008-06-27       Impact factor: 22.113

8.  Coronary artery intervention after cytostatics treatment in unstable angina patient with essential thrombocythemia. A case report and literature review.

Authors:  Hyun Chang; Chi Young Shim; June-Won Cheong; Ju-Yeon Pyo; Young Guk Ko; Donghoon Choi; Yangsoo Jang
Journal:  Korean J Intern Med       Date:  2006-06       Impact factor: 2.884

9.  Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.

Authors:  Luigi Gugliotta; Carlos Besses; Martin Griesshammer; Claire Harrison; Jean-Jacques Kiladjian; Ruth Coll; Jonathan Smith; Brihad Abhyankar; Gunnar Birgegård
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941

10.  Evaluation of repeated progression of native coronary artery stenosis by optical frequency domain imaging in a patient with essential thrombocytosis.

Authors:  Hiroto Tamaru; Kenichi Fujii; Satoru Otsuji; Shin Takiuchi; Katsuyuki Hasegawa; Kasumi Ishibuchi; Rui Ishii; Wataru Yamamoto; Sho Nakabayashi; Mikio Kakishita; Motoaki Ibuki; Shinya Nagayama; Yorihiko Higashino
Journal:  J Cardiol Cases       Date:  2018-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.